Login / Signup

Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases.

Masahiro AyanoKazuya TsubouchiK SuzukiYasutaka KimotoYojiro ArinobuKoichi AkashiTakahiko HoriuchiIsamu OkamotoHiroaki Niiro
Published in: Scandinavian journal of rheumatology (2024)
There was no evidence for a difference between the two groups in terms of discontinuation rates, efficacy, and safety. To provide further evidence, future studies using more precise dose-escalation protocols are warranted.
Keyphrases
  • idiopathic pulmonary fibrosis
  • current status
  • open label
  • interstitial lung disease
  • study protocol